Press releases
For matters related to Global communications, please contact:
Catherine Kress
Head of Communications
Email: communications@stallergenesgreer.com
Tel: +33 (0)1 55 59 26 05
Browse by year
2025-04-14 - Positive adherence impact of iPUMP® connected assistant for sublingual liquid allergen immunotherapy treatment
Positive adherence impact of iPUMP® connected assistant for sublingual liquid allergen immunotherapy treatment
Baar (Switzerland), April 14, 2025 – Stallergenes Greer, a global leader in allergy therapeutics, will present positive results from its SPEED survey at the upcoming CFA congress (Congrès Francophone d'Allergologie, the French congress of allergology) in Paris (France) April 15-18, 2025. The survey highlights both the impact of the iPUMP® connected assistant and its strong adoption among patients undergoing sublingual liquid allergen immunotherapy (SLIT) treatment.
iPUMP®, developed in conjunction with Aptar Digital Health, supports adherence to Stallergenes Greer’s personalised SLIT treatments, by ensuring patients adopt the correct dosing technique, duration and frequency of treatment. This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the treatment protocol prescribed to each patient by their physician.
The two-step SPEED survey*, which measured the impact of the iPUMP® on patient adherence and observance to SLIT treatment, showed a 15% increase in observance for patients using iPUMP®.
Moreover, for children aged 5-12, parental involvement in treatment administration dropped from 50% to 28% over three months, while the proportion of children independently taking their medication rose from 24% to 58%. Notably, 90% of parents felt reassured by the connected assistant, with half feeling completely at ease with treatment administration, compared to 36% in the non-iPUMP® group.
“Findings of the SPEED survey underscore the role of connected health solutions in improving both treatment adherence and patient confidence, which are key elements in achieving successful therapeutic outcomes,” said Dr Elena Rizova, Chief Medical Officer. “Innovation is at the heart of what we do and iPUMP®, by catering to the needs expressed by patients and healthcare professionals, meets their expectations and provides a solution to enhance treatment management and overall allergy care.”
Marcus Bates, VP Business Development & Global Head of Respiratory at Aptar Digital Health, commented, "The strong results of the SPEED survey pave the way for wider adoption of digital and connected solutions for allergy management, enabling new patients to access a simple, easy-to-use solution that can help track adherence and stay engaged to achieve better health outcomes."
By integrating digital health capabilities, Stallergenes Greer continues to drive forward its mission to develop precise, patient-centric solutions which empower individuals and improve treatment outcomes.
The results of the SPEED survey establish a strong foundation for the broader adoption of iPUMP®, supporting Stallergenes Greer’s commitment to innovation for the benefit of patients, caregivers and the medical community.
ABOUT IPUMP®
iPUMP®, developed in conjunction with Aptar Digital Health, is the first connected assistant in allergology, designed for patients initiating sublingual liquid AIT treatment with Stallergenes Greer. Launched in February 2023 in France, it has been used by a total of 9,097 patients to date.
iPUMP® features a connected pressure sensor that converts the applied force into an audible signal once the threshold is reached, confirming the treatment intake. An integrated timer marks the end of the daily dose according to the prescription, and a light indicator confirms the daily intake.
Use by children should be supervised by an adult.
This innovative and easy-to-use tool is connected to a companion mobile application and provides direct access to the personalised treatment protocol prescribed by the doctor.
iPUMP® helps support patients in improving treatment adherence to optimise impact while offering a history-tracking function for precise medication monitoring.
ABOUT APTAR DIGITAL HEALTH
Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has more than 13,000 dedicated employees in 20 countries.
For more information, visit www.aptardigitalhealth.com and www.aptar.com.
ABOUT STALLERGENES GREER
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
For more information, visit www.stallergenesgreer.com.
*SPEED real-life study (conducted by AplusA for Stallergenes Greer, carried out between 29 May and 29 November 2024, based on an online questionnaire. The objective was to measure the impact perceived by patients, after 3 months of treatment with AIT, with the use of the iPUMP® connected assistant. 104 paediatric patients aged over 5 years and 77 adolescent and adult patients aged over 13 years).
CONTACT
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Stallergenes Greer announces appointment of Andreas Amrein as Chief Executive Officer
Baar (Switzerland), March 4, 2025 – Stallergenes Greer, a global leader in allergy therapeutics, today announced that the Board of Directors has appointed Andreas Amrein as Chief Executive Officer, with effect from April 1, 2025. After more than 10 years with the company, Michele Antonelli is retiring and will step down from his role as Chief Executive Officer at the end of March 2025.
“We are delighted to welcome Andreas Amrein as Chief Executive Officer of Stallergenes Greer. He joins our company at a time of strong opportunity for continued expansion and development within allergy therapeutics, building on the excellent platform of capabilities within the firm. Andreas is a dynamic business leader with a proven track record of driving growth. His strategic vision, strong focus on execution and delivery, and extensive international experience will be key in leading Stallergenes Greer and its people through its next stage of development. We look forward to working with Andreas to realise Stallergenes Greer’s full potential and deliver sustainable value for all our stakeholders,” said Cyrus Jilla, Chairman of the Board of Directors.
“On behalf of the Board of Directors, I would like to extend my deepest thanks to Michele Antonelli for successfully steering Stallergenes Greer through a significant transformation period, while laying strong foundations for the future,” concluded Cyrus Jilla.
Andreas Amrein has more than 25 years of experience in the pharmaceutical industry and, at companies such as Novartis, Abbott and Shire Takeda, has accrued significant expertise in commercial leadership, finance, strategic planning, and business development across a variety of therapeutic areas and geographies. Since 2021, he has been a member of the Global Leadership Team and Managing Director at Advanced Clinical, a global contract research organisation.
“I am honoured to have the opportunity to lead Stallergenes Greer, a pioneer in allergen immunotherapy with a strong global footprint and an unwavering commitment to patient care. I thank the Board of Directors for the trust placed in me and am excited to start working with the company’s talented teams and build on their success as we embark on a new chapter,” stated Andreas Amrein.
ABOUT STALLERGENES GREER
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
For more information, visit www.stallergenesgreer.com.
CONTACT
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
European Commission approves the extension of the indication of Palforzia® to the treatment of toddlers with confirmed peanut allergy
Baar (Switzerland), January 9th, 2025 - Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for the treatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway).
This approval of the extension of indication of Palforzia® to toddlers, follows the July 2024 approval by the U.S. Food and Drug Administration (FDA). Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy.
“Peanut allergy is one of the most frequent food allergies. Early intervention is crucial to reduce the risks of accidental exposure and may be very important in improving long-term outcomes. The approval of Palforzia for toddlers represents for the medical community a meaningful advancement in managing allergy at a pivotal stage in a child’s development,” stated Dr Katharina Blümchen, Professor at the University of Medicine of Frankfurt, Clinic for Pediatric and Adolescent Medicine, Department of Pneumology, Allergology, Infectiology, and Gastroenterology.
“The approval of Palforzia® by the European Commission highlights the need for a treatment to help alleviate the burden of peanut allergy for young patients and their family,” said Michele Antonelli, CEO of Stallergenes Greer. “In addition to the risk of severe reactions from accidental exposure, peanut allergy can have significant psychological consequences on disease sufferers and their families while negatively impacting quality of life. We are proud of this milestone which highlights Stallergenes Greer’s commitment to the patients and healthcare professionals we serve.”
Palforzia® is designed to gradually increase the body’s ability to tolerate small amounts of peanut (desensitisation) through carefully controlled and supervised initial dose escalation, up-dosing and maintenance. The extension of the indication enables treatment to be initiated at an earlier age, thus offering young children and their families the opportunity to reduce the risk of severe allergic reactions from accidental exposure to peanut allergens, with adjustment of contraindications1
The approval is based on data from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study that was published in the New England Journal of Medicine Evidence in 2023. The study evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years old, meeting all its primary and secondary efficacy endpoints and demonstrating a favourable safety profile2
Palforzia®’s broader accessibility highlights Stallergenes Greer’s mission to bring innovative therapies to patients across all stages of life. Beyond food allergy treatments, the company offers a diverse portfolio, including sublingual and subcutaneous immunotherapies for respiratory and insect venom allergies.
ABOUT PALFORZIA®
Palforzia® is indicated by the European Medicine Agency (EMA) in all 27 European member states, Iceland, Liechtenstein and Norway, for the treatment of patients aged 1 to 17 years with a confirmed diagnosis of peanut allergy. It is indicated by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients 18 years of age and older. Palforzia® should be used in conjunction with a peanut-avoidant diet.
Palforzia® is also approved by the U.S. Food and Drug Administration (FDA) for ages 1-17 years for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. The treatment is approved for use in patients with a confirmed diagnosis of peanut allergy; Initial Dose Escalation may be administered to patients aged 1 through 17 years. Up-Dosing and Maintenance may be continued in patients 1 year of age and older. Palforzia® is to be used in conjunction with a peanut-avoidant diet. Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis.
ABOUT POSEIDON PHASE 3 STUDY
POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, clinicaltrials.gov number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of Palforzia® in peanut-allergic children aged 1 to 3 years of age in North America and Europe.
The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested Palforzia® to Stallergenes Greer in September 2023.
Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge.
In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of Palforzia® or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit double-blind, placebo-controlled food challenge (DBPCFC).
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory, food and venom allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
CONTACT
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
1. Summary of Product Characteristics. Rev 19 dec 2024
2. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300145
Palforzia®: © 2025, Société des Produits Nestlé S.A. or its affiliates
Stallergenes Greer Foundation - Science Awards for Allergy 2025: call for applications
Baar (Switzerland), January 6, 2025 – The Stallergenes Greer Foundation is pleased to announce the launch of the 2025 edition of its Science Awards for Allergy, an initiative dedicated to recognising outstanding contributions to allergy research and environmental health initiatives.
Building on the success of the previous edition, the 2025 Science Awards for Allergy focus on innovation, patient empowerment, and solutions which aim to improve quality of life for individuals with allergies through personalised solutions, cutting-edge research, and comprehensive care approaches.
The foundation will honour exceptional contributions by awarding a total of €150,000 in two categories:
- Innovation in Allergy Treatment Award
The award recognises cutting-edge research with clinical relevance in the field of allergy. It will support projects with practical outcomes and applications, which deepen knowledge of allergy treatments and inspire young researchers and clinicians. The award is expected to facilitate the implementation of innovative approaches in allergy care particularly in the areas of prevention, intervention and research. - Patient Commitment Award
This award recognises projects which integrate the perspectives of patients with allergies, as well as those of their family, foster knowledge of allergic diseases and treatments, and develop the understanding of unmet needs to improve allergy care for all. The work must contribute to better understanding, preventing and treating respiratory or food allergy diseases.
Submission Period: January 6, 2025, to November 28, 2025 (11:59 PM CET).
Eligibility: Open to individuals, researchers, medical doctors, non-profit research laboratories, associations, and organisations engaged in allergy research or patient-centered initiatives. Candidates should demonstrate innovation, impact, and practical outcomes in their work.
Rules and regulations: Detailed information about eligibility, criteria, and the application process can be found on the foundation’s website: www.stallergenesgreer-foundation.org
About the Stallergenes Greer Foundation
The Stallergenes Greer Foundation is a non-profit organisation focused on creating healthier futures for all. Guided by the One Health initiative, the foundation promotes multidisciplinary collaboration to improve the health of people, animals, and the environment.
The foundation, placed under the aegis of the Fondation de France, is philanthropically dedicated to three focus areas:
- Advancing scientific research to bolster innovation and precision medicine.
- Supporting academic initiatives to further develop future generations of allergy healthcare professionals.
- Engaging in climate action and environmental protection to progress the prevention and treatment of allergies.
The Stallergenes Greer Foundation is governed by a Board of Trustees which brings together the Managing Board and the Scientific Board. The Scientific Board is composed of four independent members:
- Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France);
- Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, Vatican City (Italy);
- Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon);
- Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)
About Fondation de France
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity and translate them into effective actions of general interest. With close to 1,000 hosted foundations, the Fondation de France supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
For further details, visit www.fondationdefrance.org.
CONTACT
Stallergenes Greer Foundation
Catherine Kress
Secretary General
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com